Overview

Incretin and CRTd.

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:
0

Participant gender:
All

Summary

Incretin therapy is a treatment for type 2 diabetes (T2DM) affected by heart failure (HF). In this study the investigators will recruit T2DM patients affected by HF with depressed ejection fraction and treated by Cardiac resynchronization therapy (CRT). These patients will randomly be treated by incretin v/s conventional hypoglicemic drugs. In this patients investigators will report at follow up CRT-d responders rate, mortality, and hospital admission for HF worsening. Incretin may reduce hospital admissions for HF in T2DM v/s conventional hypoglicemic drugs.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Campania "Luigi Vanvitelli"

Treatments:

Hypoglycemic Agents
Incretins

Criteria

Inclusion Criteria:

- aged more than 18 years, with clinical hystory of T2DM non insulin dependent, and
diagnosed failing heart with depressed ejection fraction; CRTd recipients.

Exclusion Criteria:

- T2DM in insuline therapy; renal impairment, chronic inflammatory and systemic
diseases; neoplastic diseases.